An Open-label Mass Balance Study to Investigate the Absorption, Distribution, Metabolism and Elimination of a Single Oral Dose of MEK Inhibitor [14C]GSK1120212 in Male Subjects With Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 15 Nov 2017
At a glance
- Drugs Trametinib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 04 Apr 2012 Actual patients number is 2 as reported by ClinicalTrials.gov.
- 04 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 06 Jul 2011 New trial record